Limited information on golimumab indicates that it is almost undetectable in breastmilk. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[1] Anti-TNF agents appear to reduce the levels of tumor necrosis factor and IP-10 in the milk of mothers with inflammatory bowel disease in the early postpartum period.[2] Waiting for at least 2 weeks postpartum to resume therapy suspended during pregnancy may minimize transfer to the infant.[3] However, in infants of mothers who received other monoclonal antibodies during late pregnancy, continued use while breastfeeding did not prolong their elimination by the infant. Most experts and guidelines consider golimumab to be probably acceptable to use during nursing.[4-12]
关于戈利木单抗的信息有限，表明其在母乳中几乎无法检测到。它也可能在婴儿胃肠道中部分被破坏，婴儿的吸收可能极少。[1] 抗TNF药物似乎会降低产后早期患有炎症性肠病母亲乳汁中的肿瘤坏死因子和IP-10水平。[2] 产后至少等待2周再恢复孕期暂停的治疗，可能会将药物转移至婴儿的情况降至最低。[3] 然而，对于在妊娠晚期接受其他单克隆抗体治疗的母亲所生的婴儿，母乳喂养期间继续用药并未延长婴儿对药物的清除时间。大多数专家和指南认为，哺乳期使用戈利木单抗可能是可以接受的。[4-12]
